SAVARA INC (SVRA) competitors & alternatives
Health Care · NASDAQ
SAVARA INC (SVRA)'s top competitors and alternatives — its most similar public companies — include Insmed (INSM), Ultragenyx (RARE), SPRUCE BIOSCIENCES INC (SPRB), MIRUM PHARMACEUTICALS INC (MIRM), Seaport Therapeutics, Inc. (SPTX), VIRIDIAN THERAPEUTICS ORS INC (VRDN), SOLID BIOSCIENCES INC (SLDB), AN2 THERAPEUTICS INC (ANTX), ARBUTUS BIOPHARMA CORP (ABUS), XERIS BIOPHARMA HOLDINGS INC (XERS), OMEROS CORP (OMER) and AQUESTIVE THERAPEUTICS INC (AQST). These are SAVARA INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SVRA competitors & alternatives
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
MIRUM PHARMACEUTICALS INCMIRMHealth Care
Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic…
$114.48 (as of 2026-07-22) · market cap $7.0B
-
Seaport Therapeutics, Inc.SPTXHealth Care
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics using its proprietary drug development platform.
$21.30 (as of 2026-07-22) · market cap $1.1B
-
VIRIDIAN THERAPEUTICS ORS INCVRDNHealth Care
Viridian is a clinical-stage biopharmaceutical company developing potentially differentiated monoclonal antibody therapies for thyroid eye disease and…
$19.17 (as of 2026-07-22) · market cap $2.1B
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
AN2 THERAPEUTICS INCANTXHealth Care
AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other…
$4.89 (as of 2026-07-22) · market cap $176M
-
ARBUTUS BIOPHARMA CORPABUSHealth Care
A biopharmaceutical company advancing a clinical pipeline to treat chronic hepatitis B while monetizing its intellectual property through strategic licensing…
$4.33 (as of 2026-07-22) · market cap $862M
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.38 (as of 2026-07-22) · market cap $1.5B
-
OMEROS CORPOMERHealth Care
A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem…
$9.84 (as of 2026-07-22) · market cap $703M
-
AQUESTIVE THERAPEUTICS INCAQSTHealth Care
Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film…
$3.94 (as of 2026-07-22) · market cap $496M
Not quite? Describe exactly what you want →
Peers are SAVARA INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: SAVARA INC (SVRA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.